1. Home
  2. CCJ vs ARGX Comparison

CCJ vs ARGX Comparison

Compare CCJ & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCJ
  • ARGX
  • Stock Information
  • Founded
  • CCJ 1987
  • ARGX 2008
  • Country
  • CCJ Canada
  • ARGX Netherlands
  • Employees
  • CCJ N/A
  • ARGX N/A
  • Industry
  • CCJ Other Metals and Minerals
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CCJ Basic Materials
  • ARGX Health Care
  • Exchange
  • CCJ Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • CCJ 30.8B
  • ARGX 33.0B
  • IPO Year
  • CCJ N/A
  • ARGX 2017
  • Fundamental
  • Price
  • CCJ $77.74
  • ARGX $598.89
  • Analyst Decision
  • CCJ Strong Buy
  • ARGX Strong Buy
  • Analyst Count
  • CCJ 4
  • ARGX 17
  • Target Price
  • CCJ $83.32
  • ARGX $730.07
  • AVG Volume (30 Days)
  • CCJ 4.7M
  • ARGX 366.7K
  • Earning Date
  • CCJ 07-31-2025
  • ARGX 07-31-2025
  • Dividend Yield
  • CCJ 0.11%
  • ARGX N/A
  • EPS Growth
  • CCJ 5.30
  • ARGX N/A
  • EPS
  • CCJ 0.40
  • ARGX 15.94
  • Revenue
  • CCJ $2,290,088,704.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • CCJ $8.78
  • ARGX $61.64
  • Revenue Next Year
  • CCJ $9.53
  • ARGX $32.00
  • P/E Ratio
  • CCJ $196.24
  • ARGX $34.55
  • Revenue Growth
  • CCJ 29.88
  • ARGX 82.13
  • 52 Week Low
  • CCJ $35.00
  • ARGX $475.65
  • 52 Week High
  • CCJ $80.32
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • CCJ 61.17
  • ARGX 65.83
  • Support Level
  • CCJ $77.71
  • ARGX $590.78
  • Resistance Level
  • CCJ $80.32
  • ARGX $575.48
  • Average True Range (ATR)
  • CCJ 2.51
  • ARGX 11.42
  • MACD
  • CCJ -0.35
  • ARGX 4.56
  • Stochastic Oscillator
  • CCJ 73.94
  • ARGX 83.04

About CCJ Cameco Corporation

Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: